BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 16906777)

  • 1. Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art.
    Diasio RB; Fourie J
    Drugs; 2006; 66(11):1441-63. PubMed ID: 16906777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor-targeted therapy in colorectal cancer.
    O'dwyer PJ; Benson AB
    Semin Oncol; 2002 Oct; 29(5 Suppl 14):10-7. PubMed ID: 12422309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor inhibitors and colorectal cancer.
    Meyerhardt JA; Fuchs CS
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):35-8. PubMed ID: 15685832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor as a therapeutic target in colorectal cancer.
    Cohen RB
    Clin Colorectal Cancer; 2003 Feb; 2(4):246-51. PubMed ID: 12620146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor as a target for chemotherapy.
    Vallbohmer D; Lenz HJ
    Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S19-27. PubMed ID: 15871762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors.
    Ritter CA; Arteaga CL
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):3-11. PubMed ID: 12644979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor inhibition strategies in oncology.
    Harari PM
    Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
    Raben D; Helfrich B; Bunn PA
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
    Venook AP
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR targeting of solid tumors.
    Rocha-Lima CM; Soares HP; Raez LE; Singal R
    Cancer Control; 2007 Jul; 14(3):295-304. PubMed ID: 17615536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the epidermal growth factor receptor in colorectal carcinoma.
    Kurtin SE
    Cancer Nurs; 2007; 30(4 Suppl 1):S1-9. PubMed ID: 17666985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [EGFR-targeted therapies: what's new?].
    Vignot S; Besse B; Soria JC; Milano G; Spano JP
    Bull Cancer; 2006 Jan; 93(1):13-8. PubMed ID: 16455501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The epidermal growth factor receptor as a target for colorectal cancer therapy.
    Lockhart AC; Berlin JD
    Semin Oncol; 2005 Feb; 32(1):52-60. PubMed ID: 15726506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.
    Poindessous V; Ouaret D; El Ouadrani K; Battistella A; Mégalophonos VF; Kamsu-Kom N; Petitprez A; Escargueil AE; Boudou P; Dumont S; Cervera P; Fléjou JF; André T; Tournigand C; Chibaudel B; de Gramont A; Larsen AK
    Clin Cancer Res; 2011 Oct; 17(20):6522-30. PubMed ID: 21880790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.